Drug-Eluting Device Coating Services Market Global Report 2026

The drug-eluting device coating services market size has grown strongly in recent years. It will grow from $1.04 billion in 2025 to $1.1 billion in 2026 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to the increasing incidence of cardiovascular diseases, growing adoption of drug-eluting medical technologies, rising demand for minimally invasive treatments, increasing utilization of coated cardiovascular implants, and growing demand for localized therapeutic drug delivery.

The drug-eluting device coating services market size is expected to see strong growth in the next few years. It will grow to $1.43 billion in 2030 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to increasing demand for advanced drug-release profiles, rising adoption of combination drug coatings, growing utilization of drug-eluting coatings in emerging medical device applications, increasing demand for personalized therapeutic delivery, expanding requirement for specialized coating development and validation services. Major trends in the forecast period include growing demand for precise control over drug loading and release, increasing adoption of uniform and durable drug-eluting coatings, rising demand for biocompatible coating materials, increasing emphasis on coating adhesion and long-term stability, expanding requirement for regulatory-compliant coating validation and testing.

The growing demand for localized drug delivery is expected to propel the growth of the drug-eluting device coating services market going forward. Localized drug delivery is a therapeutic approach that delivers drugs directly to the targeted site of a disease, improving treatment efficacy while minimizing systemic side effects. The demand for localized drug delivery is increasing due to the rising prevalence of chronic diseases that require targeted and sustained therapeutic interventions. Drug-eluting device coating services support localized drug delivery by applying specialized coatings that enable medical devices to release therapeutic agents in a controlled manner directly at the treatment site, enhancing clinical performance and patient outcomes. For instance, in November 2024, according to the Spanish Society of Cardiology, a Spain-based professional medical society, percutaneous coronary interventions performed exclusively with drug-coated balloons increased from 2,891 procedures in 2022 to 3,852 procedures in 2023, representing a 33.2% year-on-year increase, while the cumulative increase from 2021 to 2023 reached 92%, reflecting the growing adoption of localized drug-delivery technologies in coronary interventions. Therefore, the growing demand for localized drug delivery is driving the growth of the drug-eluting device coating services market.

Leading companies operating in the drug-eluting device coating services market are focusing on developing advanced services, such as next-generation coating services, to improve patient safety, enhance procedural efficacy, and reduce complications. Next-generation coating services refer to advanced manufacturing processes that apply therapeutic agents onto medical devices with exceptional uniformity, aiming to optimize drug transfer efficiency and minimize particulate generation. For example, in June 2023, Surmodics Inc., a US-based medical device technology company, announced FDA approval for its SurVeil drug-coated balloon (DCB), which features its proprietary drug-excipient formulation and an innovative manufacturing process. This next-generation DCB is designed to deliver a substantially lower drug dose (2.0 µg/mm²) with more uniform coating distribution. It is intended for the treatment of peripheral artery disease and has demonstrated noninferior safety and effectiveness at 24 months compared to a market-leading high-dose DCB, which may reduce the risk of downstream particulates and emboli while improving patient outcomes and potentially lowering healthcare costs associated with repeat revascularization procedures.

In February 2025, Integer Holdings Corporation, a US-based medical device contract development and manufacturing company, acquired Precision Coating Inc. for an undisclosed amount. Through this acquisition, Integer aimed to enhance its medical device coating and surface-modification capabilities while broadening its portfolio of advanced coating solutions. Precision Coating Inc. is a US-based specialized medical device coating company that provides coating and surface-treatment technologies for patient-critical medical devices.

Major companies operating in the drug-eluting device coating services market are Medtronic plc, Freudenberg Medical LLC, Integer Holdings Corporation, Viant Medical LLC, Harland Medical Systems Inc, Precision Coating Company LLC, Specialty Coating Systems Inc, Hydromer Inc, Covalon Technologies Ltd, Nordson Medical Corporation, Secant Group LLC, Sono-Tek Corporation, AST Products Inc, Formacoat LLC, Advanced Deposition & Coating Technologies Inc, Medibrane Ltd, Surgical Coatings LLC, Applied Medical Coatings LLC, Stenocoat Sp z o o, CD Bioparticles.

North America was the dominating region in the drug-eluting device coating services market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the drug-eluting device coating services market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the drug-eluting device coating services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The drug-eluting device coating services market includes revenues earned by entities through drug-polymer compatibility assessment, polymer selection and optimization, drug stability and degradation assessment, coating adhesion enhancement and coating thickness optimization. Only goods and services traded between entities or sold to end consumers are included.

This product will be delivered within 3-5 business days.